JCTLM Database: higher-order reference materials, methods and services
Details : C16RMP2R - UPLC-tandem mass spectrometry method for analysis of amyloid beta 1-40 in human CSF
Type (acronym) | rmp |
Type | reference measurement procedure |
Unique Nomination Number | C16RMP2R |
Analyte Name | amyloid beta 1-40 |
IUPAC IFCC Number | Amyloid beta 1-40 |
Method capable of Traceability of Analyte to SI or Defined Procedure | SI |
Applicable Matrices | human CSF, frozen |
Name | UPLC-tandem mass spectrometry method for analysis of amyloid beta 1-40 in human CSF |
Organization that developed Validated Method | Biomarker Research Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA |
Measurement Techniques Used | liquid chromatography tandem mass spectrometry, solid phase extraction |
Quantity | Mass concentration |
From (0) | 200 |
To (0) | 20000 |
Unit (0) | pg/mL |
From (1) | 17.4 |
To (1) | 1085.6 |
Unit (1) | pg/mL |
Level of Confidence (%) | 95% |
Peer Reviewed Publication | Qualification of a surrogate matrix-based absolute quantification method for Amyloid-beta 42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry, Korecka M. et al, ''Journal of Alzheimer's Disease, 2014, 41(2), 441-451
Analytical and clinical performance of Amyloid-beta peptides measurements in CSF of ADNIGO/2 participants by an LC-MS/MS Reference Method, Korecka M. et al, Clinical Chemistry, 2020, 66(4), 587-597
Analytical and clinical performance of amyloid beta peptides measurement in CSF of ADNIGO and ADNI2 participants by an UPLC-MS-MS reference method, Korecka M., Poster for 2018 AAIC, Alzheimer's and Dementia'', 2018, 14(7), 378
|
Comments to be published via JCTLM DB | This reference measurement method was developed and validated by Biomarker Research Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA |
Analyte Category Name | Proteins |
Non-CCQM Key Comparison Report | Commutability study - Amyloid beta 42 adjusted methods- this project focused not only on comparison of Ab42 between immunoassays: Euroimmune, Fujirebio, Roche and mass spec (UPenn) after adjustment to Ab42 CRMs, but also included analysis of Abeta 40. Data are still under review so official or published report is not available. |
Non-CCQM Key Comparison Report Hyperlink | |
---|